Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasms, Unknown Primary × Vemurafenib × 1 year × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Melanoma 8 Neoplasms 7 Thyroid Neoplasms 4 Thyroid Cancer, Papillary 4 Neoplasm Metastasis 4 Leukemia, Hairy Cell 4 Multiple Myeloma 3 Lymphoma, Non-Hodgkin 3 Carcinoma, Non-Small-Cell Lung 3 Thyroid Carcinoma, Anaplastic 2 Skin Neoplasms 2 Neoplasms by Site 2 Neoplasms by Histologic Type 2 Hematologic Neoplasms 2 Glioma 2 Colorectal Neoplasms 2 Xanthogranuloma, Juvenile 1 Wilms Tumor 1 Thyroid cancer, follicular 1 Skin Diseases 1 Sarcoma, Ewing 1 Sarcoma 1 Rhabdomyosarcoma 1 Rhabdoid Tumor 1 Recurrence 1 Ovarian Neoplasms 1 Osteosarcoma 1 Noonan syndrome 3 1 Neuroectodermal Tumors, Primitive, Peripheral 1 Neuroblastoma 1

Interventions

pembrolizumab 2 atezolizumab 2 zenocutuzumab 1 sintilimab 1 pertuzumab 1 pemigatinib 1 olaparib 1 ivosidenib 1 ipatasertib 1 entrectinib 1 cobimetinib 1 alectinib 1 Whole Genome Sequencing 1 Vemurafenib 1 Transurethral Resection of Prostate 1 Specimen Handling 1 Sequence Analysis, RNA 1 Radiosurgery 1 Paclitaxel 1 Magnetic Resonance Spectroscopy 1 HhAntag691 1 Genetic Testing 1 Genetic Profile 1 Gemcitabine 1 Fluorodeoxyglucose F18 1 FAPI-46 1 Erlotinib Hydrochloride 1 Cisplatin 1 Carboplatin 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03498521 2025-11-19

CUPISCO

Hoffmann-La Roche

Phase 2 Completed

529 enrolled 16 charts

Neoplasms, Unknown Primary

Data powered by HemOnc (CC BY 4.0) Colophon ⚡